Lannett Company, Inc. (LCI) Research

Lannett Company, Inc. operates as a U.S.-based pharmaceutical firm dedicated to the comprehensive process of developing, manufacturing, packaging, commercializing, and distributing generic versions of established brand-name drugs. Its extensive product portfolio encompasses a wide array of dosage forms, including solid oral, extended-release, topical, liquid, nasal, ophthalmic, injectable, patch, foam, buccal, sublingual, and suspension preparations. These generic medications address a broad spectrum of therapeutic areas, such as cardiovascular health, central nervous system disorders, endocrinology, gastrointestinal issues, infectious diseases, pain management, respiratory conditions, and mental health. Notable among its offerings are generic versions of critical medications such as Levothyroxine Sodium, Fluphenazine, Posaconazole, Verapamil SR, Methylphenidate, Omeprazole, and Sumatriptan Nasal spray, alongside others like Amphetamine IR tablets and cocaine hydrochloride solution. Lannett serves a broad and diverse client base, encompassing generic pharmaceutical distributors, drug wholesalers, major chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, and governmental entities. The company actively engages in strategic partnerships, maintaining supply and development agreements with key collaborators such as Summit Bioscience LLC, HEC Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and numerous other entities. Founded in 1942, Lannett Company, Inc. maintains its headquarters in Trevose, Pennsylvania.

Open Lannett Company, Inc. (LCI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.